Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novasep Reports Full Year 2013 Results

Published: Friday, March 28, 2014
Last Updated: Friday, March 28, 2014
Bookmark and Share
Results show strong growth and beating guidance.

Novasep has announced its unaudited consolidated results for the period ended December 31, 2013.

The company is excited by the performance achieved through the year including:
• 8 per cent revenue growth, reaching EUR 316m
• 15 per cent EBITDA growth and increase of almost EUR 5m and reaching EUR 38.5m, meaningfully ahead of investor guidance for the year
• Improvement in performance in every division of the business
• Net cash flow from operations of EUR 16m, from EUR 6m in 2012
• On-time and on-target performance in its key customer commitments, including the building of the largest chromatography plant located in Mourenx, expected to be operational during summer 2014

Financial results and business review
For the full year 2013, Novasep achieved sales of EUR 315.7m (plus 7.6 per cent increase vs. the same period of 2012), and adjusted EBITDA of EUR 38.5m (plus 14.6 per cent increase vs. adjusted EBITDA of the same period of 2012). This result was achieved with growth and improvement in performance in every division.

For the synthesis segment, sales increased by about plus 5.2 per cent up to EUR 155.1m: loss of sales in legacy pharma contracts have been fully compensated by increased sales in agro and specific pharma markets, in particular highly potent ingredients for cancer therapies. Division EBITDA of EUR 14.4m is growing strongly, up 18 per cent over last year as costs were contained while revenues grew.

The biopharma segment grew 14 per cent to EUR 52.5m excluding internal sales (up an even more impressive 33 per cent and up to EUR 61.2m including chromatography equipment for the Leffe project of EUR 9m). EBITDA jumped by 125 per cent up to EUR 5.4m, (plus 100 per cent excluding Leffe project equipment contribution). The revenue increase is driven both by growth of sales of equipment and company’s improved performance in the CMO biopharmaceutical segment.

The industrial biotech segment 2013 sales have remained stable (minus 0.9 per cent vs. 2012) at EUR 57.5m. At the same time, thanks to supply chain improvements, EBITDA has gone up by 19 per cent to EUR 5.7m.

The pharmachem segment shows a 9.4 per cent increase in sales (5.6 per cent in USD) and a 2.5 per cent increase in EBITDA.

The net cash flow from operations of EUR 16m, up from EUR 6.3m in 2012, was achieved through improvement in operating results coupled with decrease in working capital, mainly driven by inventories and overdues reductions. At the end of 2013, Novasep had net debt of EUR 132m (vs. EUR 128m at end 2012) and cash on hand of EUR 40m (vs. EUR 41m at end 2012).

Recent events and prospects for 2014
The new management team is on the ground and driving the business. Thierry van Nieuwenhove was appointed head of the synthesis business unit in early January. The process division has split into two different business units; biopharma, managed by Alain Lamproye, and industrial biotech, managed by Nadege Laborde.

In addition, Michel Spagnol, CEO of Novasep, was appointed chairman of the supervisory board on March 4th, 2014. The company is establishing a new management and marketing center in Lyon Gerland to be closer to its key customers, to be operational in the fourth quarter 2014.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep, Triclinic Labs Partner
Partnership will enable Novasep to offer early-stage solid-state chemistry services in North America.
Thursday, September 15, 2016
Novasep Appoints Dr. François D’Hooge as Bioconjugation Unit Manager
Dr. D’Hooge will manage Novasep’s new antibody drug conjugates (ADC) production facility in Le Mans, France, currently undergoing completion.
Tuesday, September 06, 2016
Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smart Gloves Monitor Parkinson’s Disease
URI biomedical engineering professor creating smart gloves to monitor parkinson’s disease patients.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
Cell Metabolism Linked to Spread of Cancer
Scientists discover macrophage metabolism can be attuned to prevent the spread of cancer.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos